Agilent Technologies (A) 57.65 $A
Lab Automation Global Market - Forecast to 2020
PR Newswire Europe - Mon Sep 08, 12:10PM CDT
DUBLIN, Sept. 8, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] has announced the addition of the "Lab Automation Global Market - Forecast to 2020" [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] report to their offering.
Agilent Technologies to Present at Morgan Stanley Healthcare Conference
Business Wire - Fri Sep 05, 12:50PM CDT
Agilent Technologies Inc. (NYSE: A) today announced the following webcast for the investment community:
Global Biotechnology Reagents Market 2014-2018
M2 - Fri Sep 05, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kjn7g3/global) has announced the addition of the "Global Biotechnology Reagents Market 2014-2018" report to their offering. The Global Biotechnology Reagents market to grow at a CAGR of 9.79 percent over the period 2013-2018. Biotechnology reagents are chemical compounds or substances that are added to a system to detect and examine another substance to provide a test reading. Reagents are generally used in laboratories to prepare, collect, and examine specimens from the human body for specific diagnostics. Biotechnology reagents are used in the field of research, molecular biotechnology, human immunology, genetics, diagnosis, biosciences, and education. An increase in biomedical research activities is one of the predominant trends in the market. New emerging fields such as DNA chips, metabolomics and combinational chemistry research drive the market growth. According to the report, high investment in R&D by biotechnology companies is one of the major drivers of the market. Biotechnology and pharmaceutical companies invest in the development and production of drugs, therapeutics, and diagnostics procedures for health and commercial applications. Further, the report states that one of the major challenges in the market is the presence of highly efficient automated instruments. Automated instruments enable optimal utilization of reagents, which has tempered the use of biotechnology reagents. These instruments minimize wastage and spill associated with traditional instruments as they are designed to avoid manual transfer of reagents from one container to another. Key Vendors - Agilent Technologies - BD Biosciences - Bio-Rad Laboratories - F. Hoffmann-La Roche - Sigma-Aldrich - Thermo Fisher Scientific Other Prominent Vendors - Abbott Diagnostics - Beckman Coulter (Subsidiary of Danaher) - EMD Millipore - GE Healthcare - QIAGEN - Takara Bio Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/kjn7g3/global
Is It Time to Buy Danaher Corporation's Stock?
Lee Samaha, The Motley Fool - Motley Fool - Thu Sep 04, 5:30PM CDT
Diversified industrial conglomerate Danaher Corporation remains one of the highest quality stocks in the industrial sector, but there are question marks about its prospects going forward. What should investors do with a stock that has rewarded...
First Tech Federal Credit Union on Fast Track to ROI with Verian
PRWeb - Thu Sep 04, 10:07AM CDT
First Tech Federal Credit Union recently selected Verian's cloud-based, purchase-to-pay suite. The First Tech system, which has close to 1,000 end users, was implemented in less than 90 days. The implementation included multiple Verian software modules and ten unique system integrations.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
TRADE NEWS: Agilent Technologies Introduces Tools for Next-Generation Genome Engineering
Business Wire - Thu Sep 04, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology.
Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts
M2 - Thu Sep 04, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r8nnxx/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts" report to their offering. This 7-country report will help current suppliers and potential market entrants identify and evaluate emerging opportunities in the flow cytometry markets during the next five years. The report explores future marketing and technological trends in seven countries; provides market share estimates, test volume forecasts, and instrument placements; compares features of major clinical and research flow cytometers; profiles competitors and emerging market entrants; and suggests specific product and marketing opportunities for flow cytometry instruments and reagents. Rational During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine. Key Topics Covered: I. Introduction II. Worldwide Market and Technology Overview III. France A. Executive Summary IV. Germany A. Executive Summary V. Italy A. Executive Summary VI. Japan A. Executive Summary VII. Spain A. Executive Summary VIII. U.K. A. Executive Summary IX. U.S. X. Major Product Development Opportunities XI. Design Criteria for Decentralized Testing Products XII. Alternative Market Penetration Strategies XIII. Potential Market Entry Barriers and Risks XIV. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - CellaVision - Dako/Agilent Technologies - Horiba - Iris/Danaher - Ortho-Clinical Diagnostics - Nihon Kohden - Roche - Siemens - Sysmex For more information visit http://www.researchandmarkets.com/research/r8...e_horizons
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
Agilent Unveils ClearSeq AML Panels for Cancer Research - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 6:25PM CDT
Agilent (A) launched the first product of its ClearSeq family of advanced cancer research panels, ClearSeq AML, designed in association with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University.
TRADE NEWS: Keysight Technologies Announces Best-in-Class Femto/Picoammeters and Electrometers for Research and Development of New Materials
Business Wire - Tue Sep 02, 10:00AM CDT
Keysight Technologies, Inc. today introduced the B2980A Series of femto/picoammeters and electrometers, the world's first graphical picoammeters and electrometers to confidently measure down to 0.01 fA which is 0.01 x 10-15 A, and up to 10 petaohms (P) which is 10 x 10(15) ohms.
Agilent Technologies Introduces Higher-Performance Q-TOF GC/MS System, Featuring Optimized Hardware/Software Capabilities
Business Wire - Tue Sep 02, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced the 7200B Quadrupole Time of Flight (Q-TOF) Gas Chromatography Mass Spectrometer (GC/MS) System. The system replaces the company's most advanced GC/QTOF, the 7200A, with new capabilities that will significantly boost laboratory performance.
Microlease Unveils Certified Pre-Owned Program
Business Wire - Tue Sep 02, 7:01AM CDT
Microlease, Inc. today announced the launch of Microlease Certified Pre-Owned, a comprehensive program to address growing customer demand for quality test instruments with guarantees and calibration. Microlease Certified Pre-Owned will include instruments from leading manufacturers including Keysight Technologies (formerly Agilent Technologies), Tektronix, JDSU, Anritsu, Rohde & Schwarz, and Keithley, among others.
Agilent Technologies the ClearSeq AML for next generation cancer research
M2 - Tue Sep 02, 3:51AM CDT
Agilent Technologies Inc (NYSE: A), a chemical analysis, life sciences, diagnostics, electronics and communications company, today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels
Business Wire - Tue Sep 02, 2:30AM CDT
Agilent Technologies Inc. (NYSE: A) today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Dako Launches Fast HER2 ISH Assay for New Automated Staining Platform in Europe
GlobeNewswire - Mon Sep 01, 8:13AM CDT
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics , today announced the EU launch of HER2 IQFISH pharmDx automated on Dako Omnis.
Global Nebulizers Market Industry Analysis 2014-2019 - Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers
M2 - Mon Sep 01, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9s298/nebulizers_market) has announced the addition of the "Nebulizers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global nebulizers market was valued at USD 610.0 million in 2012 and is expected to grow at a CAGR of 6.5% from 2013 to 2019, to reach an estimated value of USD 937.7 million by 2019. The global nebulizers market is segmented based on product types into pneumatic nebulizer, ultrasonic nebulizer and mesh nebulizer. In 2012, pneumatic nebulizer accounted for the largest market share of the global nebulizers market owing to its cost effective nature and easy to handle. Pneumatic nebulizers are further classified as vented and breath-actuated pneumatic nebulizers. In 2012, breath actuated pneumatic nebulizers segment accounted for the largest share of the global pneumatic nebulizers market due to factors such as cost effectiveness and efficient drug delivery. Moreover, the breath-actuated pneumatic nebulizers segment is expected to grow at the highest CAGR from 2013 to 2019 in the global pneumatic nebulizers market. Ultrasonic nebulizers are further segmented into standalone and portable ultrasonic nebulizers. Portable ultrasonic nebulizers accounted for the largest share as they are easy to handle and operate. North America accounted for the largest share in the global nebulizers market in 2012 owing to rising prevalence of respiratory diseases such as asthma, COPD and cystic fibrosis. In addition, increasing government initiatives in this region also supported the growth of nebulizers market in the North American region. Asia-Pacific was observed to be an emerging market for nebulizers and is expected to grow at the highest CAGR from 2013 to 2019. This growth was mainly attributed due to presence of large patient pool diagnosed with chronic diseases such as asthma and chronic pulmonary obstructive diseases (COPD) in this region. Also, manufacturers are expanding their operations in Asian countries such as India, China, Japan and South Korea. For example, Omron Healthcare, Inc., established its subsidiary in South Korea to sell its nebulizers in this region. Thus, all the above mentioned factors collectively supports the growth of nebulizers market in Asia-Pacific region. Some of the key players having presence in the global nebulizers market are Philips Healthcare, Omron Healthcare, GF Health Products, Inc. and PARI Respiratory, Inc. Nebulizers Market, by Product Types - Pneumatic Nebulizer - Vented Pneumatic Nebulizers - Breath-Actuated Pneumatic Nebulizers - Ultrasonic Nebulizers - Stand Alone Ultrasonic Nebulizers - Portable Ultrasonic Nebulizers - Mesh Nebulizers - Static Mesh Nebulizers - Vibrating Mesh Nebulizers Company Profiles - Agilent Technologies, Inc. - Allied Healthcare Products, Inc. - CareFusion Corporation - Covidien plc - GE Healthcare Ltd. - GF Health Products, Inc. - Omron Healthcare, Inc. - PARI Respiratory Equipment, Inc. - Philips Healthcare For more information visit http://www.researchandmarkets.com/research/l9...ers_market
Dako Sponsors European Pathology Congress for Second Straight Year
GlobeNewswire - Fri Aug 29, 8:08AM CDT
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, is again a major sponsor of the annual European Congress of Pathology.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
Global Oscilloscope Industry Report 2014-2020
M2 - Thu Aug 28, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qzdmmv/global) has announced the addition of the "Global Oscilloscope Industry Report 2014" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The oscilloscope market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Oscilloscope industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-three industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The oscilloscope industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: Chapter One Oscilloscope Industry Overview Chapter Two Asia Oscilloscope Market Analysis Chapter Three North America Oscilloscope Market Analysis Chapter Four Europe Oscilloscope Market Analysis Chapter Five Global Oscilloscope Market Analysis Chapter Six Oscilloscope Key Players Analysis Chapter Seven Oscilloscope Industry Development Trend Chapter Eight Oscilloscope New Project Investment Feasibility Analysis Chapter Nine Global Oscilloscope Industry Research Conclusions Companies Mentioned - Agilent Technologies Inc. - Danaher Corp. - Dataman Programmers Ltd - GAO Tek Incorporation - GW Instek - Hangzhou jingce Electronic Co. Ltd. - Hantek - MINIPA - OWON - PCE Iberica S.L. - RIGOL - Rohde & Schwarz GmbH & Co. - Shenzhen antaixin Electronic Co., Ltd. - TEXIO - Tekway - Teledyne LeCroy Inc. - Time Electronics - UNI-T - YangZhong wantai Electronic Instrument Co.,Ltd - Yangzhou Tuopu Electrical Technology Co., Ltd. - Yokogawa Electric - ZTEC Instruments - Fleet parts ltd. For more information visit http://www.researchandmarkets.com/research/qzdmmv/global
Lab Automation Global Market - Forecast to 2020
PR Newswire Europe - Mon Sep 08, 12:10PM CDT
DUBLIN, Sept. 8, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] has announced the addition of the "Lab Automation Global Market - Forecast to 2020" [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] report to their offering.
Agilent Technologies to Present at Morgan Stanley Healthcare Conference
Business Wire - Fri Sep 05, 12:50PM CDT
Agilent Technologies Inc. (NYSE: A) today announced the following webcast for the investment community:
Global Biotechnology Reagents Market 2014-2018
M2 - Fri Sep 05, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kjn7g3/global) has announced the addition of the "Global Biotechnology Reagents Market 2014-2018" report to their offering. The Global Biotechnology Reagents market to grow at a CAGR of 9.79 percent over the period 2013-2018. Biotechnology reagents are chemical compounds or substances that are added to a system to detect and examine another substance to provide a test reading. Reagents are generally used in laboratories to prepare, collect, and examine specimens from the human body for specific diagnostics. Biotechnology reagents are used in the field of research, molecular biotechnology, human immunology, genetics, diagnosis, biosciences, and education. An increase in biomedical research activities is one of the predominant trends in the market. New emerging fields such as DNA chips, metabolomics and combinational chemistry research drive the market growth. According to the report, high investment in R&D by biotechnology companies is one of the major drivers of the market. Biotechnology and pharmaceutical companies invest in the development and production of drugs, therapeutics, and diagnostics procedures for health and commercial applications. Further, the report states that one of the major challenges in the market is the presence of highly efficient automated instruments. Automated instruments enable optimal utilization of reagents, which has tempered the use of biotechnology reagents. These instruments minimize wastage and spill associated with traditional instruments as they are designed to avoid manual transfer of reagents from one container to another. Key Vendors - Agilent Technologies - BD Biosciences - Bio-Rad Laboratories - F. Hoffmann-La Roche - Sigma-Aldrich - Thermo Fisher Scientific Other Prominent Vendors - Abbott Diagnostics - Beckman Coulter (Subsidiary of Danaher) - EMD Millipore - GE Healthcare - QIAGEN - Takara Bio Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/kjn7g3/global
Is It Time to Buy Danaher Corporation's Stock?
Lee Samaha, The Motley Fool - Motley Fool - Thu Sep 04, 5:30PM CDT
Diversified industrial conglomerate Danaher Corporation remains one of the highest quality stocks in the industrial sector, but there are question marks about its prospects going forward. What should investors do with a stock that has rewarded...
First Tech Federal Credit Union on Fast Track to ROI with Verian
PRWeb - Thu Sep 04, 10:07AM CDT
First Tech Federal Credit Union recently selected Verian's cloud-based, purchase-to-pay suite. The First Tech system, which has close to 1,000 end users, was implemented in less than 90 days. The implementation included multiple Verian software modules and ten unique system integrations.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
TRADE NEWS: Agilent Technologies Introduces Tools for Next-Generation Genome Engineering
Business Wire - Thu Sep 04, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology.
Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts
M2 - Thu Sep 04, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r8nnxx/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts" report to their offering. This 7-country report will help current suppliers and potential market entrants identify and evaluate emerging opportunities in the flow cytometry markets during the next five years. The report explores future marketing and technological trends in seven countries; provides market share estimates, test volume forecasts, and instrument placements; compares features of major clinical and research flow cytometers; profiles competitors and emerging market entrants; and suggests specific product and marketing opportunities for flow cytometry instruments and reagents. Rational During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine. Key Topics Covered: I. Introduction II. Worldwide Market and Technology Overview III. France A. Executive Summary IV. Germany A. Executive Summary V. Italy A. Executive Summary VI. Japan A. Executive Summary VII. Spain A. Executive Summary VIII. U.K. A. Executive Summary IX. U.S. X. Major Product Development Opportunities XI. Design Criteria for Decentralized Testing Products XII. Alternative Market Penetration Strategies XIII. Potential Market Entry Barriers and Risks XIV. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - CellaVision - Dako/Agilent Technologies - Horiba - Iris/Danaher - Ortho-Clinical Diagnostics - Nihon Kohden - Roche - Siemens - Sysmex For more information visit http://www.researchandmarkets.com/research/r8...e_horizons
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
Agilent Unveils ClearSeq AML Panels for Cancer Research - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 6:25PM CDT
Agilent (A) launched the first product of its ClearSeq family of advanced cancer research panels, ClearSeq AML, designed in association with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University.
TRADE NEWS: Keysight Technologies Announces Best-in-Class Femto/Picoammeters and Electrometers for Research and Development of New Materials
Business Wire - Tue Sep 02, 10:00AM CDT
Keysight Technologies, Inc. today introduced the B2980A Series of femto/picoammeters and electrometers, the world's first graphical picoammeters and electrometers to confidently measure down to 0.01 fA which is 0.01 x 10-15 A, and up to 10 petaohms (P) which is 10 x 10(15) ohms.
Agilent Technologies Introduces Higher-Performance Q-TOF GC/MS System, Featuring Optimized Hardware/Software Capabilities
Business Wire - Tue Sep 02, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced the 7200B Quadrupole Time of Flight (Q-TOF) Gas Chromatography Mass Spectrometer (GC/MS) System. The system replaces the company's most advanced GC/QTOF, the 7200A, with new capabilities that will significantly boost laboratory performance.
Microlease Unveils Certified Pre-Owned Program
Business Wire - Tue Sep 02, 7:01AM CDT
Microlease, Inc. today announced the launch of Microlease Certified Pre-Owned, a comprehensive program to address growing customer demand for quality test instruments with guarantees and calibration. Microlease Certified Pre-Owned will include instruments from leading manufacturers including Keysight Technologies (formerly Agilent Technologies), Tektronix, JDSU, Anritsu, Rohde & Schwarz, and Keithley, among others.
Agilent Technologies the ClearSeq AML for next generation cancer research
M2 - Tue Sep 02, 3:51AM CDT
Agilent Technologies Inc (NYSE: A), a chemical analysis, life sciences, diagnostics, electronics and communications company, today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels
Business Wire - Tue Sep 02, 2:30AM CDT
Agilent Technologies Inc. (NYSE: A) today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Dako Launches Fast HER2 ISH Assay for New Automated Staining Platform in Europe
GlobeNewswire - Mon Sep 01, 8:13AM CDT
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics , today announced the EU launch of HER2 IQFISH pharmDx automated on Dako Omnis.
Global Nebulizers Market Industry Analysis 2014-2019 - Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers
M2 - Mon Sep 01, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9s298/nebulizers_market) has announced the addition of the "Nebulizers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global nebulizers market was valued at USD 610.0 million in 2012 and is expected to grow at a CAGR of 6.5% from 2013 to 2019, to reach an estimated value of USD 937.7 million by 2019. The global nebulizers market is segmented based on product types into pneumatic nebulizer, ultrasonic nebulizer and mesh nebulizer. In 2012, pneumatic nebulizer accounted for the largest market share of the global nebulizers market owing to its cost effective nature and easy to handle. Pneumatic nebulizers are further classified as vented and breath-actuated pneumatic nebulizers. In 2012, breath actuated pneumatic nebulizers segment accounted for the largest share of the global pneumatic nebulizers market due to factors such as cost effectiveness and efficient drug delivery. Moreover, the breath-actuated pneumatic nebulizers segment is expected to grow at the highest CAGR from 2013 to 2019 in the global pneumatic nebulizers market. Ultrasonic nebulizers are further segmented into standalone and portable ultrasonic nebulizers. Portable ultrasonic nebulizers accounted for the largest share as they are easy to handle and operate. North America accounted for the largest share in the global nebulizers market in 2012 owing to rising prevalence of respiratory diseases such as asthma, COPD and cystic fibrosis. In addition, increasing government initiatives in this region also supported the growth of nebulizers market in the North American region. Asia-Pacific was observed to be an emerging market for nebulizers and is expected to grow at the highest CAGR from 2013 to 2019. This growth was mainly attributed due to presence of large patient pool diagnosed with chronic diseases such as asthma and chronic pulmonary obstructive diseases (COPD) in this region. Also, manufacturers are expanding their operations in Asian countries such as India, China, Japan and South Korea. For example, Omron Healthcare, Inc., established its subsidiary in South Korea to sell its nebulizers in this region. Thus, all the above mentioned factors collectively supports the growth of nebulizers market in Asia-Pacific region. Some of the key players having presence in the global nebulizers market are Philips Healthcare, Omron Healthcare, GF Health Products, Inc. and PARI Respiratory, Inc. Nebulizers Market, by Product Types - Pneumatic Nebulizer - Vented Pneumatic Nebulizers - Breath-Actuated Pneumatic Nebulizers - Ultrasonic Nebulizers - Stand Alone Ultrasonic Nebulizers - Portable Ultrasonic Nebulizers - Mesh Nebulizers - Static Mesh Nebulizers - Vibrating Mesh Nebulizers Company Profiles - Agilent Technologies, Inc. - Allied Healthcare Products, Inc. - CareFusion Corporation - Covidien plc - GE Healthcare Ltd. - GF Health Products, Inc. - Omron Healthcare, Inc. - PARI Respiratory Equipment, Inc. - Philips Healthcare For more information visit http://www.researchandmarkets.com/research/l9...ers_market
Dako Sponsors European Pathology Congress for Second Straight Year
GlobeNewswire - Fri Aug 29, 8:08AM CDT
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, is again a major sponsor of the annual European Congress of Pathology.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery Global Oscilloscope Industry Report 2014-2020
M2 - Thu Aug 28, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qzdmmv/global) has announced the addition of the "Global Oscilloscope Industry Report 2014" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The oscilloscope market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Oscilloscope industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-three industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The oscilloscope industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: Chapter One Oscilloscope Industry Overview Chapter Two Asia Oscilloscope Market Analysis Chapter Three North America Oscilloscope Market Analysis Chapter Four Europe Oscilloscope Market Analysis Chapter Five Global Oscilloscope Market Analysis Chapter Six Oscilloscope Key Players Analysis Chapter Seven Oscilloscope Industry Development Trend Chapter Eight Oscilloscope New Project Investment Feasibility Analysis Chapter Nine Global Oscilloscope Industry Research Conclusions Companies Mentioned - Agilent Technologies Inc. - Danaher Corp. - Dataman Programmers Ltd - GAO Tek Incorporation - GW Instek - Hangzhou jingce Electronic Co. Ltd. - Hantek - MINIPA - OWON - PCE Iberica S.L. - RIGOL - Rohde & Schwarz GmbH & Co. - Shenzhen antaixin Electronic Co., Ltd. - TEXIO - Tekway - Teledyne LeCroy Inc. - Time Electronics - UNI-T - YangZhong wantai Electronic Instrument Co.,Ltd - Yangzhou Tuopu Electrical Technology Co., Ltd. - Yokogawa Electric - ZTEC Instruments - Fleet parts ltd. For more information visit http://www.researchandmarkets.com/research/qzdmmv/global
